사이언처홀딩스(SCNX)는 NASDAQ에 상장된 Healthcare · Pharmaceutical Retailers 기업입니다. 현재가 $0.46 (-1.29%), 시가총액 $0.02B, 52주 범위 $0.24 ~ $2.60.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-ac
사이언처홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사이언처홀딩스의 현재 주가는 $0.46 (-1.29%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사이언처홀딩스의 시가총액은 약 $0.02B입니다.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the